What's new?
10/07/2018

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
SOFINNOVA PARTNERS
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.otsuka.com/en/

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/

30/09/2003
10/09/2003
02/09/2003

FOR IMMEDIATE RELEASE: Ingenium Appoints Dr. Klaus Dembowsky to Vice President Drug Discovery

Munich, Germany, September 2, 2003 -Ingenium Pharmaceuticals AG announced today that Klaus Dembowsky, M. D., Ph. D., has joined the company as Vice President Drug Discovery and will lead research and development activities, focusing on advancing Ingenium’s internal drug discovery portfolio toward clinical testing. Dr. Dembowsky joins Ingenium from Bayer Corporation, where he spent over 10 years in drug discovery and development, most recently as a manager of the Bayer-Millennium collaboration for drug target discovery. “Klaus brings to us the right mix of pharmaceutical development expertise, hands-on discovery and collaboration experience and valuable research focus in both the drug classes and therapeutic areas of primary importance,” commented Michael C. Nehls, M. D., Ph. D., Chief Executive Officer of Ingenium. “At this critical juncture in Ingenium’s development as a drug discovery leader, we are thrilled to have Klaus work with us to build our internal strength and lead our research and development.”

Dr. Dembowsky has over 20 years experience in pharmaceutical research and development and academic research. Over the course of his 10-year tenure at Bayer Corporation, Dr. Dembowsky was active across all stages of drug discovery and development, including drug target identification and selection, compound optimization, pre-clinical drug development and clinical trial consultation. Most recently, Dr. Dembowsky was Project Manager and Team Leader for the Bayer- Millennium target discovery collaboration on site at Millennium’s facilities in Cambridge/ MA. Prior to Bayer, Dr. Dembowsky was Associate Professor of Physiology at the University of Heidelberg. Dr. Dembowsky has conducted extensive academic research in the area of neurobiology and has co-edited a book on recombinant proteins. Dr. Dembowsky received his Ph. D. in physiology and his M. D. from the University of Heidelberg.

Ingenium Pharmaceuticals bases its business on generating the biological information critical to the discovery, validation and development of therapeutics. Ingenium’s technologies are based on a unique functional analysis of the mammalian genome at the organism level. Using its Deductive Genomics™ approach, Ingenium has produced a portfolio of medically relevant novel biological discoveries in the areas of inflammatory bowel disease, diabetes/ obesity, and neurobiology. In addition, the company had developed complimentary biomedical discovery and validation platforms (INGENOtyping™ and INGENOtypes®), which it uses internally and provides to its partners. To date, Ingenium’s partners include Elan Corporation, F. Hoffmann-La Roche Ltd., Sequenom Inc., Oxagen Ltd and multiple academic institutions.


Visit website http://www.ingenium-pharma.com

26/08/2003
07/08/2003
28/07/2003

Servista is enabling Lloyds TSB to become the first UK bank to offer an integrated gas, electricity and telephone service to its customers. The new service, to be branded ‘Ideal from Lloyds TSB’, will be made possible by Servista’s unique managed service offering and underlying technology platform.


As the UK’s leading provider of business process outsourcing (BPO) for the emerging ‘home services’ market, Servista helps companies to unlock more value from their consumer brands by enabling them to enter new markets in a rapid, low risk manner. Servista, in conjunction with its partners, provides a complete ‘turn-key’ solution that allows multiple services to be offered and managed via one solution. Servista manages the customer journey from registration to billing to collection, and includes customer relationship management (CRM) and marketing analytics capabilities. Servista’s clients are thus able to focus on marketing new services whilst outsourcing customer management to Servista.


Courtney Sheets, CEO of Servista commented: “The deregulation of the utilities markets in the UK has opened up many opportunities for consumer brands to deliver a new proposition to their customer base, and it is exciting to see Lloyds TSB make that move today. We are delighted that Lloyds TSB selected Servista to be their expert partner in the home services market.”


Darryn Melrose, Head of Non Financial Services for Lloyds TSB’ commented: “When we started to develop our proposition, we went straight to Servista; they have unrivalled knowledge and experience in home services. We have been working with Servista for some time now in order to ensure that our service is at the very leading edge in terms of quality, convenience and value. I have been impressed by the innovation that they have brought to our offering, and I am very confident that they will enable Lloyds TSB to deliver extra-ordinary service to our customers”.


For further information, please contact
Scott Sunderman, Servista
phone: +44 (0) 20 7813 5114
email: scott.sunderman@servista.com.



Tom Buchanan/Fiona Fong, Brunswick
phone: +44 (0) 20 7404 5959
email: servista@brunswickgroup.com.


Visit website http://www.servista.com

07/07/2003
30/06/2003
17/06/2003
05/06/2003